<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Objective: To evaluate initial combination therapy with <z:chebi fb="0" ids="6801">metformin</z:chebi> plus colesevelam in drug-naïve Hispanic patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Research Design and Methods: Patients self-identified as Hispanic from a previous study were included in this exploratory post hoc analysis </plain></SENT>
<SENT sid="2" pm="."><plain>Patients were randomized to <z:chebi fb="0" ids="6801">metformin</z:chebi> plus colesevelam or <z:chebi fb="0" ids="6801">metformin</z:chebi> plus placebo </plain></SENT>
<SENT sid="3" pm="."><plain>The primary efficacy parameter was the mean change in glycated <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> (HbA1c) levels from baseline </plain></SENT>
<SENT sid="4" pm="."><plain>Results: <z:chebi fb="0" ids="6801">Metformin</z:chebi> plus colesevelam had a greater mean HbA1c reduction (-1.2 ± 0.1%) than <z:chebi fb="0" ids="6801">metformin</z:chebi> plus placebo (-0.8 ± 0.1%; P = 0.001) from mean baselines of 7.7% and 7.6%, respectively </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="1" ids="47774">Low-density lipoprotein cholesterol</z:chebi> (<z:chebi fb="0" ids="47774">LDL-C</z:chebi>), non-<z:chebi fb="1" ids="47775">high-density lipoprotein cholesterol</z:chebi>, total cholesterol, and <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> (apo) B levels were also reduced (P &lt; 0.0001 for <z:hpo ids='HP_0000001'>all</z:hpo>), while <z:chebi fb="0" ids="17855">triglyceride</z:chebi> (P &lt; 0.0001) and apoA-I (P &lt; 0.05) levels were increased with <z:chebi fb="0" ids="6801">metformin</z:chebi> plus colesevelam treatment compared with <z:chebi fb="0" ids="6801">metformin</z:chebi> plus placebo </plain></SENT>
<SENT sid="6" pm="."><plain>With <z:chebi fb="0" ids="6801">metformin</z:chebi> plus colesevelam versus <z:chebi fb="0" ids="6801">metformin</z:chebi> plus placebo, more patients achieved an HbA1c of &lt; 7.0% (75% vs 56%) and <z:chebi fb="0" ids="47774">LDL-C</z:chebi> of &lt; 100 mg/dL (49% vs 14%; both P &lt; 0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>Conclusion: <z:chebi fb="0" ids="6801">Metformin</z:chebi> plus colesevelam may be an effective initial treatment option for Hispanic patients with early type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
</text></document>